Symbicort vs Nucala
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Symbicort | US Nucala | |
|---|---|---|
| Generic name | budesonide/formoterol | mepolizumab |
| Drug class | ICS/LABA Inhaler | IL-5 Antagonist (Biologic) |
| Treats | Asthma, COPD | Severe eosinophilic asthma, COPD, nasal polyps |
| Category | Respiratory | Respiratory |
| Manufacturer | AstraZeneca | GSK |
| Year approved | 2006 | 2015 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $120M | $75M |
| Common side effects | Throat irritation, Oral thrush, Hoarseness, Headache | Headache, Injection site reactions, Back pain, Fatigue |
Frequently asked questions
Is Symbicort or Nucala better?
Neither is universally "better." Symbicort (budesonide/formoterol) and Nucala (mepolizumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Symbicort and Nucala?
Symbicort is a ICS/LABA Inhaler made by AstraZeneca, while Nucala is a IL-5 Antagonist (Biologic) made by GSK. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Symbicort has the larger estimated TV advertising budget of the two.